Key result
New dihydropyridinic calcium antagonists like manidipine and lercanidipine may offer nephroprotective effects by decreasing microalbuminuria and reducing proteinuria when combined with RAAS blockers.
Why the study?
Do calcium antagonists prevent the progression of chronic renal failure and reduce proteinuria?
Population
Patients with chronic renal failure/disease
Design
Review
Authors
Loading...
Should not yet change CKD prescribing; leaves open confirmation of added renoprotection in prospective trials.
Do calcium antagonists prevent the progression of chronic renal failure and reduce proteinuria?
Newer dihydropyridine calcium antagonists like manidipine and lercanidipine may provide nephroprotective benefits beyond blood pressure control, similar to renin-angiotensin system blockers.
Nicolás Roberto Robles (2008) conducted a review in chronic renal failure. Calcium antagonists (manidipine, lercanidipine) was evaluated. New dihydropyridinic calcium antagonists like manidipine and lercanidipine may offer nephroprotective effects by decreasing microalbuminuria and reducing proteinuria when combined with RAAS blockers.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: